Affinity of the new cephalosporin CXA-101 to penicillin-binding proteins of Pseudomonas aeruginosa.
about
Critical evaluation of ceftolozane-tazobactam for complicated urinary tract and intra-abdominal infectionsCeftolozane/tazobactam: a novel antipseudomonal cephalosporin and β-lactamase-inhibitor combinationProfile of ceftolozane/tazobactam and its potential in the treatment of complicated intra-abdominal infectionsImpact of MIC range for Pseudomonas aeruginosa and Streptococcus pneumoniae on the ceftolozane in vivo pharmacokinetic/pharmacodynamic target.In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum β-lactamases, in the thighs of neutropenic mice.Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.Ceftolozane/Tazobactam: a new option in the treatment of complicated gram-negative infections.Population pharmacokinetics of ceftolozane/tazobactam in healthy volunteers, subjects with varying degrees of renal function and patients with bacterial infections.Pan-β-lactam resistance development in Pseudomonas aeruginosa clinical strains: molecular mechanisms, penicillin-binding protein profiles, and binding affinities.β-Lactam Antibiotics Renaissance.In vitro activity of ceftolozane-tazobactam against Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals in the CANWARD study, 2007 to 2012.β-Lactam antimicrobials: what have you done for me lately?Ceftolozane/tazobactam (CXA 201) for the treatment of intra-abdominal infections.Ceftolozane/tazobactam for the treatment of complicated intra-abdominal infections.Development of novel antibacterial drugs to combat multiple resistant organisms.Crystal structures of penicillin-binding protein 3 in complexes with azlocillin and cefoperazone in both acylated and deacylated forms.Ceftolozane/Tazobactam: A Review in Complicated Intra-Abdominal and Urinary Tract Infections.Evolution of Pseudomonas aeruginosa Antimicrobial Resistance and Fitness under Low and High Mutation Rates.Investigational drugs in phase I and phase II clincial trials for the treatment of hospital-acquired pneumonia.Efficacy, pharmacokinetic and pharmacodynamic profile of ceftolozane + tazobactam in the treatment of complicated urinary tract infections.Prescribing Ceftolozane/Tazobactam for Pediatric Patients: Current Status and Future Implications.Recent Advances in the Rational Design and Optimization of Antibacterial Agents.Ceftolozane/tazobactam for the treatment of complicated urinary tract and intra-abdominal infections.What we may expect from novel antibacterial agents in the pipeline with respect to resistance and pharmacodynamic principles.WCK 5107 (Zidebactam) and WCK 5153 Are Novel Inhibitors of PBP2 Showing Potent "β-Lactam Enhancer" Activity against Pseudomonas aeruginosa, Including Multidrug-Resistant Metallo-β-Lactamase-Producing High-Risk Clones.What is the role of the new β-lactam/β-lactamase inhibitors ceftolozane/tazobactam and ceftazidime/avibactam?Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpCEfficacy of ceftolozane in a murine model of Pseudomonas aeruginosa acute pneumonia: in vivo antimicrobial activity and impact on host inflammatory response.In vitro activity of ceftolozane/tazobactam versus antimicrobial non-susceptible Pseudomonas aeruginosa clinical isolates including MDR and XDR isolates obtained from across Canada as part of the CANWARD study, 2008-16.First Penicillin-Binding Protein Occupancy Patterns of β-Lactams and β-Lactamase Inhibitors in Klebsiella pneumoniae
P2860
Q26747429-AA89F607-1CD7-425C-892A-88D8F69EA8BCQ26998883-C6E11BBB-A742-49BE-96AB-618F1C864308Q27001490-0E98689D-A642-4F2D-B3C2-1350309260D8Q34299064-E2C17872-8BE4-4E74-896E-08CADCADC353Q34320027-D6C24970-8653-4B64-A7F4-FE4E23C7C8ADQ34393008-4C620F57-6ABC-4B5C-8B6E-14BD0EDFABDCQ34688710-3A80FCC4-8FF6-44C2-82A4-119E0AFA5C1EQ35004269-308F7F8F-55FC-4C85-83B3-CAFF34C583C1Q36172484-9CC0ACDC-B4D0-4D8D-8965-9565B8D98A2AQ36683689-919DAD30-AF30-4159-A7AD-760B9A867932Q37263317-9835182F-099B-45BA-AA97-ABA76A16A07BQ38076453-7FBC63FB-7A9F-426A-A926-EE40F85DF600Q38241417-F6B6C2A8-D6BC-47AF-89AA-BB8BFF8CD643Q38296151-8945FC42-C6CD-4827-804E-9758A94F4C27Q38350301-408F7991-262A-4932-9039-F5105584266AQ38600036-A210411F-0552-4737-B7CF-6B771D9DC6FCQ38690748-8BB697BC-1B1E-4315-B894-692F8B190536Q38741337-60ABC63C-9D64-4661-B42B-3C049E660C24Q38783043-6D05AB11-080E-4D88-93BA-3229A39DB625Q38872130-96385678-F705-49F3-A970-9F7EDEB0EAB6Q38934400-D36DC7AE-D23B-4B0F-8526-A1718CEA7011Q38958278-B0489032-F603-4887-8B5E-200B74FCDD78Q39037981-7FFFC51F-FAD7-46A9-873D-8334D93E9498Q39120027-3FA03EEB-9280-4CC6-8F32-F47070A2F5A8Q40296000-4E6B12B4-D5E4-4A2E-B0DA-F8FA7E0FF734Q40550507-13AF663E-FEEA-4948-973E-D320B5A3F4ACQ41075944-E5DED7BE-DC5F-4015-89FB-77B70238E100Q44053339-08C76CEA-F953-434A-BF04-CD7F25C2237BQ49825209-572EBDF4-6BE2-4EA1-A979-1C1A5D34FEE7Q57240386-E7D074CB-83EF-4B77-A8C5-21E4C1E66FAB
P2860
Affinity of the new cephalosporin CXA-101 to penicillin-binding proteins of Pseudomonas aeruginosa.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Affinity of the new cephalospo ...... ins of Pseudomonas aeruginosa.
@en
Affinity of the new cephalospo ...... ins of Pseudomonas aeruginosa.
@nl
type
label
Affinity of the new cephalospo ...... ins of Pseudomonas aeruginosa.
@en
Affinity of the new cephalospo ...... ins of Pseudomonas aeruginosa.
@nl
prefLabel
Affinity of the new cephalospo ...... ins of Pseudomonas aeruginosa.
@en
Affinity of the new cephalospo ...... ins of Pseudomonas aeruginosa.
@nl
P2093
P2860
P356
P1476
Affinity of the new cephalospo ...... ins of Pseudomonas aeruginosa.
@en
P2093
Antonio Oliver
Bartolomé Moyá
Laura Zamorano
P2860
P304
P356
10.1128/AAC.00296-10
P407
P50
P577
2010-06-14T00:00:00Z